Basic Theophylline Information

• INN (International Nonproprietary Name): not specified
• Brand Names Available In United Kingdom: not specified
• ATC Code: not specified
• Forms & Dosages: Tablets (various strengths), Syrup/Solution (various strengths), Injectable/Vials (ampoules/vials), Prolonged‑release and Immediate‑release formulations — common packaging includes blisters (10/20/30) and bottles (60–250 mL).
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Status depends on indication and formulation; OTC / Prescription status varies by product and strength, as noted in the supplied template.

Safety, Warnings & Patient Protection

If severe palpitations, fainting, seizures, persistent vomiting or confusion occur, seek NHS 999 or A&E immediately.

Theophylline has a narrow therapeutic index and toxicity can be life‑threatening, so prompt medical attention is essential for suspected overdose.

Before prescribing or dispensing, confirm current smoking status, all medications (including over‑the‑counter and herbal remedies), pregnancy or breastfeeding status, liver disease, heart disease, seizure history and recent unexplained weight loss.

Use the product packaging and SmPC to check contraindications and exact pack size before supply.

Insist the patient receives written information and an action plan for suspected overdose advising A&E and to bring tablets and packaging.

Advise carrying a medication card stating “theophylline — requires blood monitoring” and include emergency contact details.

Immediate actions checklist:

• Call 999 for life‑threatening signs listed above.
• Stop theophylline if severe toxicity suspected and seek hospital care.
• Bring tablets, packaging and any monitoring results to A&E.

High‑Risk Groups

Elderly patients, pregnant women and those with chronic liver disease require dose reductions and closer monitoring.

Specialist review is recommended for heart failure, seizure disorders, poor nutritional status and neonates.

Document a tailored TDM plan and arrange earlier blood tests for these groups.

Interaction With Activities

Avoid driving or operating machinery if side‑effects such as dizziness, tremor or palpitations occur.

Workplace restrictions may apply if the patient has experienced seizures or syncopal episodes while taking theophylline.

Q&A: Can I Drive After Taking Theophylline?

Do not drive if you feel drowsy, dizzy, have palpitations or have had a seizure.

If stable, asymptomatic and well monitored, driving is usually permitted.

Contact the DVLA only after a seizure or other serious adverse effect, and report suspected adverse reactions to the MHRA Yellow Card scheme.

Usage Basics: Inn, Uk Brands & Legal Classification

The international nonproprietary name is theophylline for this medication class used as an oral bronchodilator and respiratory stimulant in specialist settings.

Common UK brands include prolonged‑release preparations and generics; prolonged‑release tablets such as branded MR products are used for once or twice daily dosing.

Injectable forms (as aminophylline) are occasionally used in hospitals for acute care under specialist supervision.

Legal classification in the United Kingdom is typically prescription‑only medicine (POM) for chronic outpatient use.

Some neonatal and paediatric uses are hospital‑based and specialist‑initiated and are not suitable for routine community prescribing.

Supply and brand availability vary between community pharmacies (Boots, LloydsPharmacy, independent), hospital pharmacy and NHS‑registered online vendors.

Always check the SmPC and MHRA product licence status for the specific brand before dispensing.

Dosing Guide And Missed Doses

Adult dosing depends on formulation, body weight and serum concentration monitoring.

Typical prolonged‑release adult starting doses are 200–400 mg once or twice daily depending on product and measured levels.

Some patients need individualised regimens, often totalling 300–600 mg per day under specialist direction.

Infant and child doses are weight‑based and follow neonatal or paediatric protocols; neonates with apnoea are usually managed with caffeine in many centres, and aminophylline/theophylline use is hospital‑based.

Smoking increases theophylline clearance and often necessitates higher maintenance doses, whereas stopping smoking can cause levels to rise.

Adjustments For Comorbidities

Reduce dose or extend dosing interval for hepatic impairment, congestive cardiac failure, hypothyroidism, elderly and low body weight.

Increase monitoring when starting or stopping interacting drugs such as macrolides or fluoroquinolones, or when smoking status changes.

Q&A: What If I Miss A Dose?

Take the missed dose as soon as remembered unless it is close to the next scheduled dose; do not double up.

For prolonged‑release tablets, if multiple doses are missed or symptoms recur, contact your specialist for advice rather than doubling doses.

Therapeutic Drug Monitoring & Blood Tests

Therapeutic drug monitoring is required because theophylline has a narrow therapeutic index and variable clearance between individuals.

Typical therapeutic serum concentrations for chronic therapy are approximately 10–20 mg/L, with many clinicians targeting 10–15 mg/L for maintenance and slightly higher ranges under acute hospital care.

Obtain a trough sample immediately before the next dose for MR products to guide dosing decisions.

Initial steady‑state trough levels are usually checked 3–5 days after starting or after a dose change for MR preparations, or sooner when interacting drugs are introduced.

Monitor more frequently if levels are unstable, symptoms of toxicity appear, or clinical status such as liver function or smoking status changes.

Document results in the GP record and update the patient medication card promptly.

Drug And Substance Interactions

Theophylline is mainly metabolised by CYP1A2 and is subject to many clinically significant interactions.

Strong inhibitors that raise theophylline levels include ciprofloxacin, enoxacin, erythromycin, clarithromycin, fluvoxamine and cimetidine.

Inducers that lower levels include cigarette smoking, phenobarbital, carbamazepine, rifampicin and St John’s wort.

Beta‑agonists and other sympathomimetics can aggravate tachycardia, and drugs that lower seizure threshold such as clozapine increase CNS risk when combined with theophylline.

Common OTC and herbal interactions include increased stimulant effects with caffeine and reduced levels with smoking.

Ask patients to notify prescribers before starting antibiotics or stopping smoking as either may require urgent dose adjustment and TDM.

Contraindications & Precautions

Absolute contraindications include known hypersensitivity to theophylline, aminophylline or any excipients.

Relative contraindications and precautions include seizure disorder, uncontrolled arrhythmias, severe cardiac disease, hyperthyroidism, severe hepatic impairment and unstable hypertension.

Pregnancy and breastfeeding require specialist assessment; use only if benefits outweigh risks and monitor infants for irritability or feeding issues if exposed via breastmilk.

Nutritional depletion, fever and intercurrent illness can alter clearance and increase toxicity risk.

Prescribers should screen for baseline liver and renal function, cardiac history, all current medicines, smoking and caffeine intake before initiating therapy.

• Pre‑prescription checklist for clinicians: liver tests, ECG if cardiac history, seizure history, medication review, smoking status.
• Risk definition: absolute = hypersensitivity; relative = conditions requiring dose adjustment and monitoring.

Provide written advice to patients on signs that require urgent care such as severe palpitations, vomiting or seizures.

Side Effects, Management & Reporting

Common side effects are nausea, vomiting, abdominal pain, headache, insomnia, tremor and restlessness.

Less common but serious effects include arrhythmias, hypotension and seizures, which are medical emergencies.

Rare immunologic reactions such as skin rash or urticaria require immediate drug cessation and evaluation.

For mild symptoms, assess adherence and consider dose adjustment; for moderate to severe signs, obtain serum theophylline level and treat as per emergency protocols.

Report all serious or unexpected reactions to the MHRA Yellow Card scheme and document in the GP record.

Indications & Off‑Label Uses

Licensed indications typically include adjunct bronchodilator therapy for chronic stable asthma or COPD when inhaled therapies are insufficient.

Theophylline can be used in selected cases of nocturnal asthma and historically in hospital management of acute severe asthma.

Off‑label and hospital uses include apnoea of prematurity in units that still use methylxanthines other than caffeine and some specialist use for refractory COPD symptoms.

• Licensed: adjunct bronchodilator for chronic asthma/COPD when inhaled options are inadequate.
• Off‑label/hospital: neonatal apnoea protocols in some units, refractory COPD symptom relief.

NICE and BTS/SIGN guidance favour inhaled therapies such as LABA, LAMA and ICS combinations as first‑line treatments.

Initiation and monitoring are usually performed by specialist respiratory teams, with clear TDM plans if therapy continues in primary care.

Mechanism Of Action & Pharmacology

Theophylline is a methylxanthine bronchodilator that acts as a non‑selective phosphodiesterase inhibitor and an adenosine receptor antagonist.

These actions increase intracellular cyclic AMP leading to bronchodilation and improved diaphragmatic contractility.

At lower concentrations theophylline has modest anti‑inflammatory effects which may contribute to clinical benefit in chronic therapy.

Oral absorption is good; immediate‑release preparations peak in about 1–2 hours, while prolonged‑release formulations produce delayed peaks and steady concentrations with once or twice daily dosing.

Hepatic metabolism via CYP1A2 makes clearance sensitive to smoking, age, genetics, hepatic function and interacting drugs.

Access & Purchase Options In The United Kingdom

Theophylline is generally a prescription‑only medicine (POM) and is issued by GPs for chronic therapy or by hospital specialists on initiation.

Community pharmacies such as Boots, LloydsPharmacy and independent branches dispense prescriptions and NHS e‑prescribing and electronic repeat dispensing support follow‑up.

Hospital pharmacy supplies IV aminophylline and handles aseptic preparations for inpatient use.

Online pharmacies may supply with a valid prescription and patients should use only NHS‑registered or GPhC‑registered vendors.

In our online pharmacy, theophylline is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Costs are subject to NHS prescription charges in England and exemptions apply; prescriptions are free in Scotland, Wales and Northern Ireland for most patients.

Alternatives Matrix: Comparative Options

First‑line inhaled therapies include short‑acting beta2‑agonists such as salbutamol for relief and long‑acting bronchodilators such as salmeterol, formoterol and tiotropium for maintenance.

Inhaled corticosteroids and combination LABA/ICS or LAMA/LABA combinations provide better safety and efficacy profiles than oral theophylline for most patients.

Oral leukotriene receptor antagonists such as montelukast are alternatives in selected patients.

Pros and cons checklist: inhaled therapies generally safer and preferred by NICE and BTS/SIGN, while theophylline is considered when inhaled regimens are insufficient or unsuitable and monitoring is available.

Patient Counselling & Pharmacist Communication Style

Explain that the medicine is prescribed to help open the airways and reduce breathlessness rather than acting like an inhaler puff.

Emphasise dosing schedules and the difference between prolonged‑release and immediate‑release tablets, including the instruction not to crush MR tablets.

Highlight the need for blood tests, when they will occur and that results guide dose changes.

Discuss common side‑effects and interactions, particularly with ciprofloxacin, macrolides, smoking and caffeine.

Provide a written medication card showing theophylline, monitoring dates and emergency contact details.

• Counselling checklist: purpose, dosing, MR vs IR, TDM, interactions, what to do with vomiting.
• Leaflet format: brief steps for toxicity, contact numbers and when to seek emergency care.

Document counselling in the pharmacy record and notify prescribers of adherence or adverse effects requiring review.

Storage, Handling & Dispensing Tips

Store at room temperature away from moisture and heat and keep in the original packaging to avoid confusion between MR and IR forms.

Ensure labelling highlights “Do Not Crush/Chew” for MR formulations and include clear administration times on the label.

Advise patients to bring remaining tablets and packaging to A&E or clinic if toxicity is suspected for accurate identification.

For IV aminophylline in hospital settings, follow local aseptic preparation, labelling and stability guidance and monitor expiry after reconstitution.

Dispose of unwanted medicine via NHS medicines take‑back schemes rather than household rubbish.

Key Clinical Evidence & Prescribing Trends

Guidelines and literature from 2017 to 2025 show declining routine use of theophylline because of its narrow therapeutic index and the advance of modern inhaled therapies.

Evidence supports restricted use as add‑on therapy in selected chronic asthma and COPD patients when inhaled combinations are insufficient.

Some trials show modest functional benefit but an increased rate of adverse events requiring careful therapeutic drug monitoring.

Neonatal practice has shifted toward caffeine for apnoea of prematurity in many units, reducing routine theophylline use in neonates.

• NICE/BTS/SIGN: favour inhaled combinations and reserve theophylline for specialist‑selected cases.
• Practice point: document documented benefit/risk and consult specialist for initiation or complex dosing.

Regulation, Prescribing Framework & Reporting

Theophylline products are POM and regulated under the MHRA, with individual brands holding separate licences and SmPCs that must be consulted for exact dosing and contraindications.

Prescribers should follow NICE guidance and local formularies; hospital initiation with a clear TDM plan is common before community continuation.

Pharmacovigilance requires reporting adverse events via the MHRA Yellow Card scheme and recording therapy and monitoring in the GP record.

Use electronic repeat dispensing where appropriate and liaise with medicines optimisation teams for supply or brand switches.

Delivery Across United Kingdom